The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.
The firm aims to offer a clinical service next year for predicting immunotherapy response and adverse immune reactions.
The companies plan to commercialize MIODx's immune sequencing technology for diagnostic purposes.
The companies are planning to develop individual disease diagnostics, and then a universal diagnostic from a single blood test.
Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.
The researchers found disease-related signatures in the immune repertoire of affected patients as well as changes associated with treatment.
Enpicom will initially offer separate solutions on its ImmunoGenomiX platform for research and clinical applications in oncology but seeks to expand into other disease areas.
Adaptive will work with NCI's Cancer Therapy Evaluation Program to use its ImmunoSeq platform for biomarker discovery in clinical trials.
The company recently raised $8 million and is looking to partner with other firms interested in antigen discovery and diagnostic development.
The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.
Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.
CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.
The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.
In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.